This novel AMP is abundantly expressed in the dermis and epidermis of healthy human skin but is downregulated under conditions of inflammation and disease, suggesting that CXCL14 fights bacteria at the earliest stage of infection [40,41] and may indirectly suppress cancer initiation by preventing infection-induced inflammation. This evidence concerns the gene CXCL14 and infection.